Harrow, Inc. Proceeds from Debt, Net of Issuance Costs
Harrow, Inc. (HROW) reported Proceeds from Debt, Net of Issuance Costs of $244.38 million for the 9-month period ending 2025-09-30, per its 10-Q filed 2025-11-10.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromDebtNetOfIssuanceCosts · last filed 2025-11-10
- Harrow, Inc. proceeds from debt, net of issuance costs for the quarter ending 2016-03-31 was $2.77M.
- Harrow, Inc. proceeds from debt, net of issuance costs for the quarter ending 2015-12-31 was -$38.00K.
- Harrow, Inc. proceeds from debt, net of issuance costs for the quarter ending 2015-09-30 was $0.00.
- Harrow, Inc. proceeds from debt, net of issuance costs for fiscal 2015 was $9.27M.
| Period end | Proceeds from Debt, Net of Issuance Costs 3 month | Proceeds from Debt, Net of Issuance Costs 6 month | Proceeds from Debt, Net of Issuance Costs 9 month | Proceeds from Debt, Net of Issuance Costs 12 month |
|---|---|---|---|---|
| 2025-09-30 | $244.38M 10-Q · filed 2025-11-10 | |||
| 2016-03-31 | $2.77M 10-Q · filed 2016-05-12 | $2.73M derived: sum of 2 quarters · filed 2017-03-21 | $2.73M derived: sum of 3 quarters · filed 2017-03-21 | |
| 2015-12-31 | -$38.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-21 | -$38.00K derived: sum of 2 quarters · filed 2017-03-21 | $9.27M 10-K · filed 2017-03-21 | |
| 2015-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-14 | $9.30M 10-Q · filed 2016-11-14 | ||
| 2015-06-30 | $9.30M 10-Q · filed 2016-08-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Kardigan, Inc. (KARD) | United States | $1.346B |